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Abstract
Background: Shared decision-making (SDM) is recommended for men facing prostate cancer (PC) screening
decisions. We synthesize the evidence on the comparative effectiveness of SDM with usual care.
Methods: We searched academic and grey literature databases, and other sources for primary randomised
controlled trials (RCTs) published in English comparing SDM to usual care and conducted in primary and specialised
care. We assessed the individual study risk of bias, and calculated the study-specific and pooled relative risks (RR) or
standardised mean differences (SMD) [with 95% confidence intervals (CI)] to perform random-effects meta-analyses for
SDM-related and patient outcomes.
Results: Four RCTs comparing SDM to usual care, involving 1760 men, were included. SDM improved knowledge
(SMD 0.23, 95%CI 0.02 to 0.43; 2 RCTs), but was not different to usual care in reducing either patient participation in
prostate-specific antigen (PSA) testing (RR 1.03, 95%CI 0.90 to 1.19; 2 RCTs) or decisional conflict (SMD -0.04, 95%CI -0.23
to 0.15; SMD -0.05, 95%CI -0.24 to 0.14; 2 RCTs). Individual trial estimates (46.7%) also suggest that SDM may reduce or
neutralise physicians’ tendency for PSA screening, and may improve the accuracy of patients’ perception of lifetime-
risks and men’s views towards screening. There was no evidence on the effects of SDM on health outcomes. The
studies represent various interventions and outcomes and are prone to risk of bias.
Conclusions: There is currently insufficient evidence to support a clear association of SDM on patient- and SDM-
related outcomes for decisions about PSA testing. Further research needs to assess the clinical effectiveness of SDM
using well-defined SDM interventions and outcomes. It should address the absence of evidence, particularly on health
outcomes.
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Background
Prostate cancer (PC) is the second most commonly diag-
nosed non-skin malignancy and the fifth leading
cancer-related cause of death for men worldwide [1, 2]. PC
incidence varies mainly by age, race/ethnicity and family
history [2, 3]. It continues to rise, mostly in Western devel-
oped countries [1, 4] and is expected to increase to 1.7 mil-
lion cases and 499,000 new deaths by 2030 globally [2].
Screening for PC aims to diagnose the disease at an
early stage when the chances of successful treatment are
higher, thus increasing the possibility of cure. Indeed the
widespread use of screening tests, especially prostate-spe-
cific antigen (PSA) in the general population, has im-
proved early PC detection, thereby increasing the
incidence of diagnosed PC. The balance between the ben-
efits and harms of screening remains controversial how-
ever [5]. PC testing has led to false-positive results,
complications and over diagnosis (risk estimates: up to
67%) that may lead to further unnecessary investigations
and overtreatment [6]. Data about the reduction in mor-
tality due to PC screening have also shown conflicting re-
sults. Population-based trials have shown no significant
differences in PC mortality after 13, 15 or 20 years [7–9],
while others showed reduced risks of metastases and
PC-specific mortality after 11 and 13 years [10–12]. In
addition, treatment for screened-detected PC can lead to
potential adverse outcomes (e.g. urinary and erectile dys-
function, loss of fertility, chemotherapy and/or hormone
therapy side effects), distress, impaired quality of life, and
increased healthcare costs [10, 13, 14]. Guidelines for PC
screening consequently vary worldwide. Recommenda-
tions for PC testing by some health authorities are becom-
ing more consistent by setting constraints and only
screening well-informed men [15–19]. Others have devel-
oped specific population-based screening programs [20].
Some others are against population-based screening, but
still provide testing on demand [21–23]. In addition, the
screening practices for men at risk of PC and the age at
which screening should be started for example, are still
being debated [24]. These factors, together with the
fast-growing availability of cancer testing and treatment
technology, make the process of medical decision-making
even more challenging for both patients and healthcare
professionals (HCP), leading to value-laden decisions that
are preference-sensitive.
Shared decision-making (SDM) is viewed as the best
practice model for physician-patient-communication
regarding preference-sensitive medical decisions [25].
Experts, major task force associations, policy makers and
clinical guidelines strongly advocate SDM discussions as
a critical step preceding medical decisions for PC
screening [15, 17, 19, 22–24, 26]. SDM may have the po-
tential of reducing the overuse of options with unclear
benefits while enhancing the use of beneficial options
and reducing variations in practice [27, 28]. To-date,
however, there is no single definition of SDM and no
consensus on how to integrate SDM in practice resulting
in varying levels of SDM implementation. A systematic
review showed that key criteria recommended for SDM
[29] supporting the principle of deliberation [30] was
fulfilled by only 34.8% of the studies evaluating SDM for
decisions about PC screening [31].
Increasing research has focused on the development of
decision aids (DAs) as a way to promote informed med-
ical decisions and to improve patient outcomes [32]. Evi-
dence on the effects of SDM is not restricted to DAs
however. In addition, provision of DAs does not ensure
patient participation in decision-making nor does it war-
rant an SDM approach to medical decisions. The role of
SDM in improving patient outcomes as compared to
usual care remains unclear. We sought to evaluate the
evidence on the effectiveness of SDM as compared to
current clinical practice for patient- and SDM-related
outcomes. We focused on the population of men facing
preference-sensitive decisions for PC screening.
Methods
Our study followed a protocol based on the recommenda-
tions for systematic reviews of healthcare interventions
[33, 34] and the PRISMA guidelines (Additional file 1)
[35]. The methods to identify and select studies are de-
scribed in detail elsewhere [31].
Search strategy
Using terminology compatible with SDM and prostate
cancer, we searched for RCTs using MEDLINE Ovid,
EMBASE (Elsevier), CINHAL (EBSCOHost), The
Cochrane Library (Wiley), PsychINFO (EBSCOHost) and
Scopus from the period of database inception up to March
2015 (see Additional file 2). We searched for grey litera-
ture using clinical trial registers (clinicaltrials.gov and
ISRCTN), the WHO search portal (http://www.who.int/
ictrp/search/en/) and the Ottawa Hospital Research Insti-
tute website (http://www.ohri.ca//) by accessing the re-
cords between February and August 2016, and searching
for the trials registration number in Medline and PubMed.
We also searched Google Scholar and the system for In-
formation on Grey Literature in Europe (http://open-
grey.eu/). Additionally, we screened the reference lists of
included studies, relevant systematic reviews and clinical
guidelines. We also contacted (June 2015 to January 2017)
the authors of abstracts for which full-text publications
could not be located.
Eligibility criteria
We included peer-reviewed randomised controlled trials
(RCTs) published in English, from any country, investi-
gating SDM for PC screening in primary or specialised
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care (general practice, community clinics, ambulatory
care, hospital and private care services), which: 1) com-
pared SDM to usual care regardless of the intervention
target (patients and/or HCP, surrogates or family mem-
bers), and 2) reported outcome data in quantitative for-
mat. We further limited study eligibility to RCTs that
fulfilled the criteria for SDM based on the most promin-
ent SDM framework [29, 36] considering bi-directional
deliberation as central and mandatory in SDM [37]. As
detailed elsewhere, this process led to a set of studies of
higher SDM quality [31].
Outcomes’ relevance is generally directed by the person-
alisation of the SDM process, patients’ health status and
the available choices, resulting in a non-standardised set
of outcomes to evaluate the success of SDM. We focused
on the outcomes of knowledge, screening participation,
risk perception, patient satisfaction, decisional conflict, de-
cisional regret, quality of life, symptoms and mortality.
Selection of studies and data extraction
Two authors independently screened the titles and ab-
stracts of all citations, and examined the full-text of eli-
gible publications. Data extractions were carried out by
one author, and independently verified by a second au-
thor. Discrepancies in study selection and data extrac-
tions were moderated by a third author. Data were
extracted using standardised data collection forms devel-
oped a-priori. For each study, one author extracted data
elements including the bibliographic details, design,
country and setting, characteristics of study populations
and interventions, and outcome data. Studies reported
across more than one publication were treated as one
unit. We used the classification system recommended by
Shay and Lafata [38] to group outcomes into Affective-
cognitive, Behavioural and Health outcomes.
Study quality
Two authors independently assessed in duplicate the
quality features of the included studies without the cal-
culation of a composite score following available recom-
mendations [34, 39]. Differences were resolved by
discussion. We rated the adequacy of the studies’ core
items for internal validity (risk of bias) including gener-
ation of random sequence, concealment of allocation at
randomisation, blinding (patients, healthcare providers
and outcome assessors), intention-to-treat (ITT) and
similarity between groups at baseline. We considered
bias due to attrition of at least 20% to be of significant
concern; adequate ITT when authors analysed partici-
pants based on their original group allocation; and ad-
equate follow-up if all participants were followed-up for
the same length of time. We also assessed whether stud-
ies defined primary and secondary outcomes, inclusion
and exclusion criteria, ‘a-priori’ sample size and the type
of funding sources.
Statistical analysis
Where data were sufficiently reported, for each study out-
come we calculated the unadjusted risk ratios (RR) or the
standard mean differences (SMD) and the 95% confidence
intervals (CI) with RevMan, version 5.3.5 (http://commu
nity.cochrane.org/). We pooled data in meta-analyses
when at least two RCTs reported appropriate data. Miss-
ing standard deviations (SD) were estimated using estab-
lished techniques [34]. We report the summary statistics
with their 95% CI, and regard p < 0.05 as statistically
significant. We quantified heterogeneity using the I2 statis-
tic, for which values of 25%, 50%, and 75% represent low,
moderate, and high levels of heterogeneity [40]. Data not
combined in meta-analyses were analysed based on the in-
dividual trial estimates. We anticipated heterogeneity due
to diversity in populations and interventions and thus per-
formed all analyses under random-effects [34]. We tabu-
lated the effect sizes and synthesised all results narratively.
Results
Identification of studies
Of 270 full-text articles examined in detail, nine fulfilled
all SDM criteria. Five of these investigated the compara-
tive effectiveness of SDM with usual care [41–45]. Figure 1
shows the flow of study identification and selection.
Study and population characteristics
The summary characteristics of the included studies are
reported in Table 1. The studies, published between
2003 and 2013, were conducted in the USA (n = 3) and
Australia (n = 1). Three parallel-RCTs (75%) comprised
1048 patients individually randomised to intervention
groups while one cluster-RCT randomised 712 patients
with 120 physicians and 55 waiting areas. Participants
were recruited from general or internal medicine primary
care clinics including urban/suburban, academic, medical
group practices or university-hospital affiliated clinics. All
studies defined PC screening as testing with PSA. The
men’s age range was 54–63 years with a mean age of 59.5
(SD7.5; 3 RCTs) and the target-age for study inclusion was
40–74 years. Patient demographics varied widely across
studies. Where reported, 76.6% (range: 56.6–90.8%) of
men were White, 76.9% (range: 71.5–80.0%) were married,
76.45% (range: 30.4–89.5%) had at least high school edu-
cation, and 46.9% (range: 42.5–57.5%) were in full- or
part-time employment. At least 56.7% of all participating
men were screened with PSA before study enrolment, and
12.4% of men in three RCTs reported a family history
of PC. Between 13 and 120 family or internal medi-
cine (i.e. faculty, resident and academic) physicians
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participated in the studies and had 2–40 years of ex-
perience in two RCTs.
Intervention characteristics
All RCTs and study interventions aimed at and contained
elements to facilitate or foster SDM between patients and
physicians (Table 1). All RCTs also fulfilled the three key
SDM features [29, 36] and bi-directional deliberation [37]
as previously illustrated [31]. The interventions were de-
livered before decision-making, either within the time of
scheduled visits [43, 44] or before consultations [41, 42,
45] as an attempt to empower patients and to encourage
participation in decision-making. Men were recom-
mended to review the material before consultation [41, 43,
44], to discuss their concerns with their doctors [45] or
were specifically activated [41]. Three RCTs [42–45] used
patient-directed interventions, and one RCT [41] used
patient-physician targeted interventions. Only one RCT
used a multifaceted strategy [41]. The interventions were
self-administered, and delivered on-site [41, 45] or at
home [42–44], in a web-based or (printed) paper-based
material or both. Only two RCTs considered healthcare
literacy for the development or pilot testing of interven-
tions [42, 45]. Two RCTs evaluated two different SDM
interventions and usual care [41, 43, 44]. Their content in-
cluded mostly educational information about PC and
screening for physicians and patients as well as the links
to informational material from established organisations
(e.g. the Centers for Disease Control and Prevention). The
content of usual care was incompletely described in
most studies.
Risk of bias in the methods of included studies
No trial fulfilled all the core criteria of internal validity,
based on current standards [34] (Table 2). The trials were
at risk of selection bias as only two (50%) had adequate
random sequence generation and allocation concealment.
Studies were also vulnerable to performance and detection
biases since blinding of HCP and participants, and out-
come assessors were adequate in only two (50%) and one
(25%) RCTs respectively. Two RCTs (50%) had at least
20% attrition for some outcomes and only two (50%) re-
ported the use of ITT techniques to deal with missing
data. One RCT (25%) was potentially at risk of chance bias
although it purposely had more physicians knowing the
group in which patients were allocated (ratio of 1:3:3 be-
tween groups) in order to free other potential biases. Men
in one RCT were followed-up in 6–16 weeks. Reporting of
Fig. 1 Identification and selection of studies
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participants’ inclusion and exclusion criteria and calcula-
tion of sample size and power were adequate in two (50%)
and one (25%) RCTs respectively. All RCTs measured the
interventions’ success by definition of primary outcome(s),
but data were under-reported for some outcomes in three
RCTs. Non-profit institutions funded all RCTs.
Effectiveness of SDM interventions on outcomes
Five of the nine outcomes of interest were reported in
quantitative format (Table 3). Data were sparsely reported
across study outcomes limiting the ability to conduct
meta-analyses for most cases. Table 4 shows the individual
effect estimates from trial data not pooled in meta-analyses.
Affective-Cognitive outcomes
Knowledge Meta-analysis of two RCTs demonstrated a
small but significant effect of SDM, compared to usual
care, on improving knowledge of PC (e.g. natural history
and risk factors) and screening (SMD 0.23, 95%CI 0.02
to 0.43, p = 0.03; I2 = 0%) (Fig. 2). There was no signifi-
cant heterogeneity between trials (I2 = 0%, p = 0.48).
Patient satisfaction Individual trial effect estimates
showed no significant differences between usual care
and SDM (with or without web-based patient activation)
intervention groups with respect to the level of satisfac-
tion with medical visits [41].
Risk perception Individual trial effect estimates showed
that significantly more men in the SDM group were
likely to give a correct estimate of the lifetime risk of
developing PC (incidence - correct within 10%: RR 3.40,
95%CI 2.16 to 5.36, p = 0.00001) and dying from PC
(mortality - correct within 2%: RR 13.22, 95%CI 4.30 to
40.66, p = 0.00001) [45].
Behavioural outcomes
PSA testing for prostate cancer Meta-analysis of two
RCTs demonstrated no significant differences between
SDM and usual care in the number of men who pre-
ferred or were interested in undergoing individualised
PSA testing, with no significant heterogeneity between tri-
als (RR 1.03, 95%CI 0.90 to 1.19, p = 0.66; I2 = 0%) (Fig. 3).
Individual effect estimates of two trials showed similar
results (Table 4). In one RCT, the number of chart-docu-
mented patients for whom PSA tests were ordered by
clinicians was not significantly different between groups
[42]. Another RCT showed no significant differences be-
tween SDM intervention groups and usual care with re-
spect to the number of patients who ordered PSA tests
[43]. In the same RCT however, physicians reported sig-
nificantly less men with ordered PSA tests in the SDM
intervention groups (Web-based DA vs. Usual Care: RR
0.91, 95%CI 0.84 to 0.99, p = 0.02; Paper-based vs. Usual
Care: RR 0.90, 95%CI 0.83 to 0.98, p = 0.02).
In one cluster-RCT, the individual effect estimates
showed significantly less physicians in the SDM group
with patient activation making recommendations towards
PSA testing (RR 0.56, 95%CI 0.38 to 0.84, p = 0.004) [41].
Although the trial showed a similar pattern for the SDM
group without patient activation, the effect was only mar-
ginally significant (RR 0.74, 95%CI 0.55 to 1.00, p = 0.05).
Similarly, more physicians in the SDM group with patient
activation were more neutral in recommending PSA test-
ing (RR 3.58, 95%CI 1.59 to 8.06, p = 0.002) than physi-
cians in the SDM group with no patient activation (RR
2.45, 95%CI 1.04 to 5.76, p = 0.04), although both were
statistically significant. In another RCT, the effect esti-
mates suggested a small, but not significant effect that
men in the SDM group tend to weigh their views towards
reasons in favour of undergoing PSA testing [45].
Decisional conflict Meta-analysis of two RCTs demon-
strated no significant differences between SDM and
usual care in the level of conflict or uncertainty in mak-
ing medical decisions (Combination 1, SMD -0.04,
95%CI -0.23 to 0.15, p = 0.66; Combination 2, SMD
-0.05, 95%CI -0.24 to 0.14, p = 0.59) (Fig. 2). There was
no significant heterogeneity between trials (I2 = 0%; p =
0.59–0.67). However, the effect estimates of one trial
showed that men in the SDM group had significantly lower
scores of decisional conflict on the factors contributing to
Table 3 Outcomes reported in the included studies
Green = quantitative data; Yellow = qualitative data; Red = no outcome data
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uncertainty subscale (SMD -0.57, 95%CI -0.84 to −
0.29, p < 0.0001) (Table 4) [45].
Discussion
In this systematic review with meta-analysis, the association
of SDM with patient outcomes for decisions about PSA
testing, as compared to usual care, is inconclusive. SDM is
often discussed by policy makers and professional bodies as
the best practice model for the physician-patient communi-
cation [46], and continues to be highly (guideline-) recom-
mended for medical decisions about PC screening. Many
HCP apply elements and features of SDM with a broader
scope in their clinical practice, for example using patient-
centred communication and patient activation strategies.
We found, however, a very low volume of empirical re-
search fulfilling the criteria for SDM in which various SDM
interventions are compared to usual care (n = 4).
Although the interventions varied in characteristics
and content, the study / interventions were aimed at and
contained elements for fostering SDM. The outcomes of
interest for this review also varied widely across studies
in both quantity and reporting quality. While screening,
knowledge and decisional conflict are the most reported
SDM process-related outcomes, decisional regret, pa-
tient satisfaction or risk perception are scarcely reported,
and no study reported on health outcomes. Moreover,
no study fulfilled all the methodological quality criteria
assessed. Besides sample sizes being modest, the studies
Fig. 2 Comparison of knowledge and decisional conflict between SDM and Usual Care for men facing decisions for prostate cancer screening.
SDM, Shared Decision Making; SD, standard deviation; N, total number of patients in the analysis; SMD, standard mean differences; CI, confidence
interval; df, degrees of freedom; I2, heterogeneity between trials; EB, Evidence-Based. * Questionnaires were mailed three days post-consultations
Fig. 3 Comparison of men’s intention/preference/interest for screening between SDM and Usual Care for men facing decisions for prostate
cancer screening. SDM, Shared Decision Making; SD, standard deviation; N, total number of patients in the analysis; RR, relative risks; CI,
confidence interval; df, degrees of freedom; I2, heterogeneity between trials; EB, Evidence-Based. * Questionnaires were mailed
3 days post-consultations
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are prone to high risk of bias mainly due to problems in
the generation of the random sequence, blinding of out-
come assessors, and having an attrition rate of at least
20% for some outcomes.
The evaluated literature represent in their majority
White (76.6%), middle-aged (range: 54 to 63), married
(76.6%) men from Western countries, mainly the USA,
faced with decision-making about individualised PSA
testing, who were recruited from general or internal
medicine. Most men had PSA testing before the study
and a great proportion reported a family history of PC.
The participating HCP were family and internal medi-
cine physicians in all studies and surprisingly there were
no urologists at all. SDM interventions were mostly de-
veloped for and directed at men facing PSA screening
decisions, included elements to inform and educate, and
were delivered before the decision-making consultations.
Finally, the results from this review are based on
published data. This review should thus be considered
within this context.
Despite this diversity and methodological limitations,
our meta-analyses showed a small but significant effect of
SDM interventions in improving knowledge of PC and
screening, but no significant differences between SDM
and usual care in reducing patient participation in PSA
testing and decisional conflict. Interestingly, the patients
from two RCTs were heavily (68–83%) screened before
enrolment, and a larger than expected proportion of
patients reported a family history of PC. This background
information may be a factor influencing men’s decision for
(less) PSA testing and the (lower) likelihood of men start-
ing any decision-making process. Our meta-analyses
showed the same direction of effect across studies how-
ever, and no significant between-study heterogeneity.
Although 53.4% (n = 8) of the individual trial estimates
showed no difference between SDM and usual care, 46.7%
(n = 7) also suggest an association of SDM with improved
outcomes. SDM may reduce or neutralise the tendency of
physicians to order or recommend PSA testing and may
improve the accuracy of patients’ perception of lifetime-
risks for PC morbidity and mortality. In the latter [45],
around 70% of men had an education of high school or
less and men’s estimate of the lifetime risk of dying from
PC was highly significant (RR 13.22, 95%CI 4.30 to 40.66;
p < 0.00001). Although lower-literacy has been associated
with an individual’s overestimation of risk perception [47],
high-literacy individuals may also benefit from the educa-
tional interventions developed for low-literacy individuals
[48]. Furthermore, an increased level of understanding
and health knowledge are thought to positively influ-
ence decision-making and health behaviours. Remark-
ably, we found no evidence on the effects of SDM
versus usual care on decisional regret and on very
important health outcomes including mortality,
quality of life, and symptoms. This absence of evi-
dence does not mean that SDM does not have a
beneficial effect on patient outcomes at individual or
group levels however. Finally, men and physicians
were the target of multifaceted interventions in only
one RCT [41]. Of note, the included studies reported
no cost data.
Future research
Our findings are applicable to the development of future
SDM interventions for decisions about PSA testing and
our evaluation of the available evidence highlights a
major knowledge gap. Future studies warrant further
focus. Only a few studies fulfilled all SDM criteria sug-
gesting that SDM is not yet fully adopted in practice
despite guideline recommendations. Some guidance for
SDM implementation may therefore be necessary.
Whether patient activation without all the mandatory
elements of SDM generates the same effects, and
whether SDM is cost-effective compared to usual care
remain questions for future research. Considering the
levels of literacy and understanding may help explain the
association between SDM and health outcomes. Future
studies also need to address the barriers in the imple-
mentation of SDM e.g. physicians’ education, time con-
sumption, patients’ responsibility and literacy. This
could also guide SDM research in other areas of
medical practice. Very importantly, the fact that at
least 75% of the patients were Caucasian and married
clearly indicates the need for assessing the impact of
SDM among other racial and ethnic groups, and
across different socio-economic strata. Future research
could also help clarifying whether predefinition of
study populations based on potential modifiers such
as PSA pre-screening and family history of PC can
impact the effect of SDM.
Current research could benefit from a more complete
description of all interventions and outcome tools.
Standardisation of the definition and objectives of SDM
could lead to a clearer definition of the outcomes that
are best for assessing SDM and its (clinical) effective-
ness, and to guide the reasons for outcome selection.
The outcomes used to measure the effectiveness of SDM
is a topic under debate due to the individualisation of
the SDM process. However, to understand the full
impact of SDM, one needs to consider the type of deci-
sions made and the extent to which SDM may actually
affect health outcomes. Whether patients experience the
health outcomes they expect, prefer or to which they feel
unfavourably disposed could further guide the investiga-
tion of SDM. Future research should therefore address
the absence of evidence on the effect of SDM on these
outcomes. Future studies should also consider that inter-
ventions directed at both HCP and patients have been
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most effective in improving SDM-related and health out-
comes [27]. Finally, larger and more methodologically
sound studies could help confirming the findings from
this review.
Strengths and limitations
To our knowledge, this is the first systematic review
about SDM compared to usual care for decisions about
PC screening. Compared to other reviews [27], ours
evaluates the effect of (higher quality) SDM implementa-
tion on both SDM-related and patient outcomes with a
focus on PC testing. We searched for international lit-
erature with no restriction on countries or type of HCP.
Our review also benefits from the inclusion of RCTs
thus allowing the estimation of causal effects with lower
risk of bias. In addition, our comprehensive search strat-
egy comprised terms relevant to decision-making includ-
ing SDM and DAs. We included studies published in
English only and although the academic databases were
searched up to March 2015, we made considerable
efforts to identify all relevant studies. We also searched
for grey literature by accessing the records retrieved
from several sources between February and August
2016. By contacting authors between 2015 and 2017, we
increased the chances of identifying more of the latest
literature and full-texts with more complete data. Apart
from using thorough electronic and manual searches, we
conducted in-duplicate screening and study selection by
applying a broad inclusion criteria at screening and
full-text evaluation, and considered studies regardless of
whether a specific decision was promoted.
We restricted our review to studies that fulfilled all
SDM framework criteria [31] because of the continuing
gaps in the conceptualisation and implementation of
SDM. Our SDM framework is based on the SDM model
by Charles et al. [29], the most prominent approach of
viewing SDM with only one SDM concept [49] support-
ing the principle of bi-directional deliberation in keeping
with Elwyn et al. [30]. This rigorous and focused
approach allowed us to identify studies that integrated
the key elements of SDM. The assessment was based on
reported data, which cannot exclude the possibility of
underreported SDM characteristics in other studies.
Nevertheless, our review represents the results of studies
with higher quality SDM implementation. Furthermore,
to increase the precision of the effect estimates, we in-
corporated meta-analyses where possible, and assessed
the risk of bias of individual studies.
The results from our systematic review are mainly lim-
ited by the quantity and methodological quality of the
available literature. Only a few studies fulfilled the SDM
framework and compared SDM to usual care. In
addition, there is a dearth of data for nearly half of the
outcomes of interest and the outcomes varied in the
measurements used and reporting quality. The studies
tend to focus primarily on SDM process-related out-
comes and do not report on health outcomes. Thus, the
few meta-analyses that we could incorporate contained
two studies at most. Furthermore, the interventions’
content, especially usual care, were not fully described;
and not only the studies were prone to high risk of bias
but sample sizes were generally modest.
Conclusions
A few studies that currently fulfil the criteria for SDM
also assess the comparative effectiveness of SDM with
usual care for decisions about PC screening. The studies
comprise various SDM-fostering interventions and out-
comes of variable reporting quality. SDM may improve
knowledge and patient-perception of risk, and may re-
duce the tendency of physicians to recommend PSA
testing. SDM may be similar to usual care in reducing
patient participation in PSA testing, and in improving
patient satisfaction and decisional conflict. There is in-
sufficient evidence to support a clear association of
SDM on patient-important and SDM-related outcomes
for decisions about PSA testing. Future research needs
to assess the clinical effectiveness of SDM using
well-defined SDM interventions and outcomes. It should
address the absence of evidence especially of health out-
comes and costs.
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Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 3, 
Table 4, 
Figure 2, 
Figure 3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  8-11 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Table 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  na 
DISCUSSION 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
11 
  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  13 
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
No external 
or specific 
funding 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097 
For more information, visit: www.prisma-statement.org 
 
 
 
Additional file 2. Search strategy for OVID Medline. 
Item Searches 
1 exp Decision Making/ or Decision Making, Organizational/ or Decision Trees/ or Decision 
Making/ or Decision Support Techniques/ or Decision Support Systems, Clinical/ or Decision 
Making, Computer-Assisted/ or exp Computer-Assisted Instruction/ or exp Patient 
Participation/ or exp Professional-Patient Relations/ or exp "Attitude of Health Personnel"/ or 
Counseling/ or exp Health Communication/ 
2 exp Informed Consent/ 
3 (choice behavior or decision making or shared decision making).mp,tw. 
4 (informed adj3 (consent or choice* or decision*)).mp,tw. 
5 ((decision* or decid*) adj4 (support* or aid* or tool* or instrument* or technolog* or technique* 
or system* or program* or algorithm* or process* or method* or intervention* or 
material*)).mp,tw. 
6 (decision adj3 (board* or guide* or counseling)).mp,tw. 
7 (computer* adj4 decision making).mp. 
8 (patient adj3 (participation or involvement or cent#d care)).mp,tw. 
9 ((risk communication or risk assessment or risk information) adj4 (tool* or method*)).mp,tw. 
10 interact* health communication*.mp,tw. 
11 (interact* adj (internet or online or graphic* or booklet*)).mp,tw. 
12 (interact* adj4 tool*).mp,tw. 
13 ((interact* or evidence based) adj3 (risk information or risk communication or risk presentation 
or risk graphic*)).mp,tw. 
14 adaptive conjoint analys#s.mp,tw. 
15 or/1-14 
16 (Prostat* adj3 (Neoplasm* or Cancer or tumo?r* or carcinoma)).mp,tw. 
17 exp Prostatic Neoplasms/ 
18 16 or 17 
19 15 and 18 
20 (letter or letter$ or editorial or historical article or anecdote or commentary or note or case 
report$ or case study).pt,sh. 
21 (animals not humans).sh. 
22 20 or 21 
23 19 not 22 
24 exp Randomized Controlled Trial/ or exp clinical trial/ 
25 randomized controlled trial.pt. 
26 randomized controlled trial.sh. 
27 controlled clinical trial.pt. 
28 random allocation.sh. 
29 double blind method.sh. 
30 single blind method.sh. 
31 or/24-30 
32 31 not 22 
33 exp clinical trial/ or exp Clinical Trials as Topic/ 
34 clinical trial.pt. 
35 ((singl$ or doubl$ or trebl$ or trpl$) adj25 (blind$ or mask$)).ti,ab. 
36 (clin$ adj25 trial$).ti,ab. 
37 (random$ or placebo$).ti,ab. 
38 (PLACEBO or RESEARCH DESIGN).sh. 
39 or/33-38 
40 39 not 22 
41 40 not 32 
42 exp EVALUATION STUDIES/ 
43 (comparative study or follow up studies or prospective studies).sh. 
44 (control$ or prospectiv$ or volunteer$).ti,ab. 
45 or/42-44 
46 45 not 22 
47 46 not (32 or 41) 
48 23 and (32 or 41 or 47) 
 
 
